STOCK TITAN

Aligos Therapeutics, Inc. - ALGS STOCK NEWS

Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.

Company Overview

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics to address significant unmet medical needs in liver and viral diseases. Founded in 2018 and headquartered in South San Francisco, California, the company leverages decades of drug development expertise and a science‐driven approach to design therapies for conditions such as chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). The pipeline includes a range of investigational agents such as oral capsid assembly modulators, thyroid hormone receptor beta (THR-β) agonists, siRNA candidates, and other modalities that target multiple aspects of disease pathways.

Core Business and Therapeutic Focus

Aligos Therapeutics focuses on two primary disease areas:

  • Viral Diseases (Chronic Hepatitis B): Utilizing innovative small molecule capsid assembly modulators, the company aims to disrupt the hepatitis B viral lifecycle by reducing key viral markers including HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg. This approach is designed to not only provide chronic viral suppression but also to serve as the backbone for combination regimens aimed at achieving a functional cure.
  • Liver Diseases (MASH): The company is developing a best-in-class THR-β agonist designed to address metabolic dysfunction-associated steatohepatitis. By reducing liver fat and affecting key non-invasive biomarkers, this candidate has demonstrated robust reductions in liver fat content as measured by MRI-PDFF, with potential implications in improving histological outcomes and mitigating fibrosis.

Aligos supports its innovative pipeline with a strong commitment to rigorous clinical trials and strategic partnerships. Its agents are under evaluation in multiple phases of clinical studies, with study designs that emphasize safety, pharmacokinetics, tolerability, and efficacy across different patient populations.

Pipeline and Scientific Rationale

The company’s pipeline showcases several advanced drug candidates:

  • ALG-000184: A potent oral small molecule capsid assembly modulator (CAM-E) intended for CHB patients. It targets the hepatitis B virus lifecycle by interfering with the formation and function of covalently closed circular DNA (cccDNA), thereby reducing viral replication and antigen expression. Preclinical and early clinical data indicate strong antiviral activity and sustained viral suppression in both HBeAg-positive and HBeAg-negative subjects.
  • ALG-010133, ALG-020572, and ALG-125097: Additional oligonucleotide-based drug candidates in the CHB portfolio that further underline the company’s multifaceted approach to viral inhibition through complementary mechanisms of action.
  • ALG-055009: A THR-β agonist candidate aiming to treat MASH. Clinical studies have demonstrated its potential in reducing liver fat significantly and modulating lipid profiles, suggesting benefits for patients with metabolic dysfunction-associated liver disease. Its favorable pharmacokinetic profile and tolerability promise an improved treatment paradigm for patients requiring long-term therapy.

Strategic Collaborations and Clinical Development

Aligos Therapeutics has established multiple collaborations and trial partnerships to advance its clinical programs globally. The company collaborates with research institutions and partnering biotechs to sponsor and conduct pivotal clinical trials. Its recent clinical trial collaborations have featured innovative study designs including randomized, double-blind, placebo-controlled trials to evaluate both monotherapy and combinatory approaches with existing standard-of-care drugs. The creation of these collaborations supports robust clinical data generation and reinforces the company’s comprehensive strategy to address significant unmet needs across diverse patient populations.

Competitive Positioning and Industry Impact

Within the competitive landscape of liver and viral therapeutics, Aligos Therapeutics distinguishes itself by adopting a multi-pronged approach to drug development. By focusing on innovative mechanisms such as capsid assembly modulation and THR-β agonism, the company targets both viral suppression and metabolic modulation effectively. This contrasts with traditional monotherapy approaches which may not fully address the complexities of chronic hepatitis B or MASH. The company’s portfolio, underpinned by advanced science and strategic partnerships, positions it well within a highly competitive market that demands next-generation therapeutics capable of achieving both safety and durable efficacy.

Research and Development Excellence

Drawing upon a deep reservoir of R&D expertise, Aligos Therapeutics employs state-of-the-art technology and a rigorous scientific process to optimize its candidates. Detailed pharmacokinetic studies and dose-escalation clinical trials characterize their commitment to achieving linear pharmacokinetics, adequate target engagement, and potent antiviral effects without significant adverse events. This approach underscores the company’s dedication to building a robust scientific foundation for its product candidates while maintaining clear regulatory compliance and safety profiles.

Market Significance and Value Proposition

Aligos Therapeutics’ value proposition lies in its novel therapeutic approaches that address diseases with substantial unmet need. By focusing on critical endpoints such as viral biomarker suppression and liver fat reduction, the company establishes itself as an innovative force in the treatment of CHB and MASH. Its science-led, methodical approach to drug development communicates a clear message: the integration of advanced molecular mechanisms with stringent clinical evaluation provides a potentially transformative impact on patient outcomes. This positioning is critical for stakeholders and investors who seek comprehensive insights into the company’s strategic objectives and scientific rigor.

Conclusion

In summary, Aligos Therapeutics, Inc. represents a paradigm of innovation in the biopharmaceutical sector dedicated to improving patient care through best-in-class therapies. The company’s comprehensive pipeline, ranging from capsid assembly modulators for chronic hepatitis B to THR-β agonists for MASH, illustrates its broad commitment to tackling diseases that have long challenged conventional treatment paradigms. With extensive collaborations, robust clinical programs, and an unwavering commitment to research excellence, Aligos Therapeutics embodies the critical balance between scientific innovation and clinical pragmatism in a competitive and evolving therapeutic landscape.

Rhea-AI Summary

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced it will release its first quarter 2021 financial results on May 10, 2021, after market close. The company focuses on developing novel therapeutics for viral and liver diseases, particularly chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, Aligos aims to leverage its team's extensive drug development experience to advance its pipeline of targeted antiviral therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
Rhea-AI Summary

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the appointment of James Scopa, J.D., MBA, to its board of directors on April 27, 2021. CEO Lawrence Blatt stated this addition supports Aligos' growth as it transitions towards mid-stage clinical trials for chronic hepatitis B. Scopa brings over 30 years of life sciences experience as an investor and advisor, positioning him to provide strategic guidance. He has previously held significant roles at MPM Capital and Deutsche Banc Alex. Brown, enhancing Aligos' leadership as it expands in viral and liver disease therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
management
-
Rhea-AI Summary

Aligos Therapeutics has commenced patient dosing in its ongoing study of ALG-000184, a drug candidate targeting chronic hepatitis B (CHB). This study evaluates ALG-000184's ability to inhibit viral replication by measuring HBV DNA and RNA levels. The company aims to combine ALG-000184 with other therapies to achieve better treatment outcomes. Preliminary data from previous trials indicate a favorable safety profile. Initial data on safety and antiviral activity are expected in the second half of 2021, contributing to Aligos' goal of improving CHB treatment regimens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary

Aligos Therapeutics (NASDAQ: ALGS) reported strong financial results for Q4 and the full year 2020, with cash reserves of $243.5 million following a successful IPO raising $167.2 million. The company advanced two drug candidates, ALG-010133 and ALG-000184, into clinical trials for Chronic Hepatitis B (CHB) and expects to generate safety and antiviral activity data in 2021. However, net losses reached $108.5 million for the year, up from $52.3 million in 2019, reflecting increased R&D expenses of $79.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing of its first drug candidate, ALG-010133, in chronic hepatitis B (CHB) patients as part of the ALG-010133-101 study. This proprietary molecule aims to reduce viral S-antigen levels, pivotal for HBV replication. Preclinical studies show promising inhibition of S-antigen. Currently, 72 healthy volunteers have been dosed, indicating an acceptable safety profile. Results from the initial patient cohorts are expected in the second half of 2021. Aligos aims to develop a treatment regimen that may lead to a functional cure for CHB.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections. The presentation highlighted in vivo evidence of potent virus inhibition in infected hamsters, achieving a 3.5 log10 reduction in viral RNA. ALG-097111 showed high selectivity with an IC50 of 7 nM, indicating its potential as a targeted therapeutic option amid COVID-19's evolving strains. CEO Lawrence Blatt emphasized its importance for untreated and vaccine-resistant patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
clinical trial covid-19
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) will present four posters at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 4-6, 2021. The presentations will showcase progress in their chronic hepatitis B (CHB) drug candidates, ALG-010133 and ALG-000184, currently in Phase 1a/b studies. Notable findings include ALG-010133's promising preclinical efficacy and pharmacokinetics, and ALG-000184's safety and tolerability data. These trials aim to develop effective combination therapies against CHB.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.54%
Tags
none
-
Rhea-AI Summary

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence Blatt will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 PM ET. The presentation will include a virtual Q&A session, with the webcast recording available for 30 days afterward. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, the company aims to lead in antiviral therapies using its extensive drug development expertise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.15%
Tags
conferences
-
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) recently presented at the RespiDART & Emerging Viruses 2020 meeting, showcasing advancements in their SARS-CoV-2 therapeutic candidate, ALG-097111. The presentation underscored the development of a multiplex screening platform to identify selective inhibitors for the viral 3CLpro protease, essential for viral replication. ALG-097111 demonstrated significant inhibition without affecting human cathepsin L, highlighting its potential as a targeted treatment for SARS-CoV-2. Collaborations with KU Leuven were pivotal in these developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
none
Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced a collaboration with Merck to leverage its oligonucleotide platform technology for developing therapies targeting non-alcoholic steatohepatitis (NASH) and potentially other conditions. The agreement includes an upfront payment and up to $458M in development milestones along with tiered royalties on sales. Aligos will focus on designing and optimizing oligonucleotides, while Merck will handle clinical development and commercialization. This collaboration aims to address the critical need for effective NASH treatments amidst growing liver disease concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none

FAQ

What is the current stock price of Aligos Therapeutics (ALGS)?

The current stock price of Aligos Therapeutics (ALGS) is $7.14 as of April 1, 2025.

What is the market cap of Aligos Therapeutics (ALGS)?

The market cap of Aligos Therapeutics (ALGS) is approximately 43.9M.

What is the primary focus of Aligos Therapeutics?

Aligos Therapeutics focuses on developing novel therapeutics to address unmet medical needs in liver and viral diseases, particularly targeting chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH).

Which therapeutic areas does Aligos address?

The company targets viral diseases, primarily chronic hepatitis B, as well as liver diseases, including MASH, using innovative small molecule candidates and oligonucleotide-based therapeutics.

What is ALG-000184 and its significance?

ALG-000184 is an oral small molecule capsid assembly modulator developed for chronic hepatitis B. It disrupts the viral lifecycle by targeting key viral markers and shows sustained antiviral effects in clinical studies.

How does the THR-beta agonist candidate, ALG-055009, work?

ALG-055009 is designed to modulate thyroid hormone receptor beta function, leading to significant reductions in liver fat and associated non-invasive biomarkers. It aims to improve outcomes in patients with metabolic dysfunction-associated steatohepatitis.

What strategic collaborations has Aligos Therapeutics pursued?

Aligos has engaged in various clinical trial collaborations with research institutions and biotech partners to sponsor and conduct comprehensive randomized, double-blind, placebo-controlled studies that assess the safety and efficacy of its drug candidates.

How does Aligos differentiate itself in a competitive market?

By employing a multi-faceted approach that involves novel mechanisms like capsid assembly modulation and THR-beta agonism, Aligos addresses complex disease pathways more comprehensively than traditional monotherapy approaches, thereby positioning itself uniquely in the biopharma sector.

Where is Aligos Therapeutics headquartered and when was it founded?

The company is headquartered in South San Francisco, California, and was founded in 2018, establishing itself as a clinical-stage biopharmaceutical innovator.

What are the long-term clinical development strategies of Aligos?

Aligos is focused on advancing its candidates through all stages of clinical development by generating robust clinical data, ensuring rigorous regulatory compliance, and engaging in meaningful strategic collaborations to support its comprehensive pipeline.
Aligos Therapeutics, Inc.

Nasdaq:ALGS

ALGS Rankings

ALGS Stock Data

43.90M
4.70M
11.58%
34.03%
20.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO